表紙
市場調査レポート

米国の病院の腫瘍マーカー検査市場

2016 Emerging Strategies for the US Hospital Tumor Marker Testing Market

発行 Venture Planning Group 商品コード 258887
出版日 ページ情報 英文 567 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。

Local License: 同一事業所内

Back to Top
米国の病院の腫瘍マーカー検査市場 2016 Emerging Strategies for the US Hospital Tumor Marker Testing Market
出版日: ページ情報: 英文 567 Pages
概要

当レポートは、米国の腫瘍マーカー検査市場について調査分析し、世界市場と技術の概要、米国市場の現状と将来予測を提供するほか、主な製品開発機会、市場参入戦略などを検証し、主要企業プロファイルも含め、概略以下の構成でお届けいたします。

イントロダクション

世界市場と技術の概要

  • 癌の統計と病因
    • 乳癌
    • 肺癌
    • 結腸・直腸癌
    • 前立腺癌
    • 胃癌
    • 白血病
    • リンパ癌
    • 口腔癌
    • 皮膚癌
    • 子宮癌
    • 卵巣癌
    • 膀胱癌
  • 主な現在/新興の癌診断検査
    • イントロダクション
    • 腫瘍マーカーの分類
    • ACTH
    • アルファフェトプロテイン(AFP)
    • β2ミクログロブリン
    • CA 15-3/27.29
    • CA 19-9
    • CA-125
    • カルシトニン
    • 癌胎児性抗原(CEA)
    • エストロゲン・プロゲステロン受容体
    • フェリチン
    • ガストリン
    • ヒト絨毛性ゴナドトロピン(HCG)
    • インスリン
    • NSE
    • 潜血
    • パップスメア/HPV
    • 前立腺酸性フォスファターゼ(PAP)
    • 前立腺特異抗原(PSA)
    • 扁平上皮癌関連抗原(SCC)
    • T・Bリンパ球
    • TdT
    • サイログロブリン
    • 組織ポリペプチド抗原(TPA)
    • 生化学腫瘍マーカー
    • 腫瘍遺伝子
    • ポリペプチド増殖因子
    • 異所性ホルモン
    • コロニー刺激因子
    • リンフォカイン
    • 免疫組織化学染色
    • 新興の腫瘍マーカー
  • 装置レビューと市場のニーズ
  • 現在/新興の技術
    • モノクローナル・ポリクローナル抗体
    • 免疫測定
    • 分子診断
    • 染色体分析
    • 人工知能
    • フローサイトメトリー
    • 二次元ゲル電気泳動(2-DGE)
    • バイオセンサー
    • 競合/補完技術

米国市場

  • エグゼクティブサマリー
  • ビジネス環境
  • 市場構造
  • 市場規模と成長率、主要サプライヤーの売上高・装置設置・市場シェア

主な製品開発機会

  • 試薬キットと試験システム/パネル
  • 装置
  • コンピューター、ソフトウェア、オートメーション
  • 付属品

分散型検査製品の設計基準

代替的な市場普及戦略

  • 内部開発
  • 共同事業協定
  • 大学との契約
  • 分散型検査市場の流通戦略
    • マーケティングのアプローチ
    • 製品の複雑性
    • 顧客の選好
    • 既存のサプライヤー
    • 新興のサプライヤー
    • 主な流通業者のタイプ
    • 市場セグメント

潜在的な市場参入障壁とリスク

  • 市場の成熟
  • 費用抑制
  • 競合
  • 技術面での優位性と限界
  • 特許権保護
  • 規制上の制約
  • 分散型検査市場の課題

競合企業プロファイル

  • Abbott
  • AdnaGen
  • Applied Gene Technologies
  • Arca
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • 栄研化学
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • 富士レビオ
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • Kreatech
  • 協和メデックス
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Otho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • タカラバイオ
  • Targeted Diagnostics & Therapeutics
  • 東ソー
  • Veridex
  • 和光純薬工業
  • Wallac/PE
  • Zila

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: VPTM14057

This new report from VPGMarketResearch.com contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including:

Table of Contents

Introduction

Worldwide Market and Technology Overview

  • A. Cancer Statistics and Etiology
    • 1. Brest Cancer
    • 2. Lung Cancer
    • 3. Colon and Rectum Cancer
    • 4. Prostate Cancer
    • 5. Stomach Cancer
    • 6. Leukemia
    • 7. Lymphoma
    • 8. Oral Cancer
    • 9. Skin Cancer
    • 10. Uterine Cancer
    • 11. Ovarian Cancer
    • 12. Bladder Cancer
  • B. Major Current And Emerging Cancer Diagnostic Tests
    • 1. Introduction
    • 2. Tumor Marker Classification
    • 3. ACTH
    • 4. Alpha-Fetoprotein (AFP)
    • 5. Beta-2 Microglobulin
    • 6. CA 15-3/27.29
    • 7. CA 19-9
    • 8. CA-125
    • 9. Calcitonin
    • 10. Carcinoembrionic Antigen (CEA)
    • 11. Estrogen and Progesterone Receptors
    • 12. Ferritin
    • 13. Gastrin
    • 14. Human Chorionic Gonadotropin (HCG)
    • 15. Insulin
    • 16. NSE
    • 17. Occult Blood
    • 18. PAP Smear/HPV
    • 19. Prostatic Acid Phosphatase (PAP)
    • 20. Prostate-Specific Antigen (PSA)
    • 21. Squamous Cell Carcinoma Antigen (SCC)
    • 22. T and B Lymphocytes
    • 23. TdT
    • 24. Thyroglobulin
    • 25. Tissue Polypeptide Antigen (TPA)
    • 26. Biochemical Tumor Markers
      • ADA
      • B-Protein
      • PNP
      • 5'-Nucleotidase
    • 27. Oncogenes
      • Abl/abl-bcr
      • AIB1
      • BCL-2
      • BRCA1
      • CD44
      • C-fos
      • C-myb
      • C-myc
      • CYP-17
      • Erb-B
      • HPC1
      • N-myc
      • P40
      • P51
      • P53
      • PIK3CA
      • PTI-1
      • Ras
      • Reg
      • Sis
      • Src
      • 28. Polypeptide Growth Factors
      • Basic Fibroblast Growth Factor
      • Beta-TGF
      • Cachectin (TNT)
      • Calmodulin
      • ECFR
      • Nerve Growth Factor (NGF)
      • Epidermal Growth Factor (EGF)
      • Ornithine Decarboxylase
      • Transferrin
      • Transforming Growth Factor-Alpha
    • 29. Ectopic Hormones
    • 30. Colony Stimulating Factors
    • 31. Lymphokines
      • Alpha-Interferon
      • B Cell Growth Factors
      • B Cell Growth Factor (BCGF)
      • Gamma-Interferon
      • Interleukin-1 (IL-1)
      • Macrophage Activating Factor
    • 32. Immunohistochemical Stains
    • 33. Emerging Tumor Markers
      • N-Acetylglucosamine
      • Actin
      • Alpha-Actin
      • Antineuronal Antibodies
      • 7B2
      • B72.3
      • Bax
      • BCD-F9
      • BLCA-4
      • Blood Group Antigens A,B,H
      • CA 50
      • CA 72-4/TAG-72
      • CA 195
      • CA-242
      • CA-549
      • CAM 26
      • CAR-3
      • Cathepsin-D
      • Chromogranin A and B
      • Cluster 1 Antigen
      • Cluster-5/5A Antigen
      • CTA
      • CU18
      • DR-70
      • DU-PAN-2
      • Endometrial Bleeding Associated Factor
      • Endostatin
      • Epithelial Membrane Antigen
      • Feulgen Hydrolysis
      • Fibronectin
      • FSH
      • (1->3)-L-fucosyltransferase
      • Gastrin-Releasing Peptide (GRP)
      • GDCFP-15
      • Glucagon
      • Glycoamines
      • H23
      • Her-2
      • Human Carcinoma Antigen
      • HPA
      • HSP27
      • Intermediate Filaments
      • Cytokeratins/CK18/Cyfra 21-1
      • Desmin
      • Gliofibrillary Acid Protein
      • Neurofilaments
      • Vimentin
      • KA 93
      • Kinases
      • KP16D3
      • LAI
      • Leukocyte Common Antigen
      • Lewis Antigens
      • Lysophosphatidic Acid (LPA)
      • Ma 695/Ma 552
      • MABDF3
      • MAG
      • ME1
      • Minactivin
      • MN/CA9
      • MSA
      • Mucin Cancer Antigen (MCA)
      • Multiple Tumor Suppressor 1
      • Myosin
      • NEA-130
      • NMP22
      • OA-519
      • Opiod Peptides
      • P-glycoprotein
      • Pancreatic Oncofetal Antigen (POA)
      • Placental Lactogen
      • PR92
      • Proliferative Index, Ki-67
      • Px
      • RB Inactivation/Deletion
      • Ret
      • SCCL 175
      • Selectin
      • Sialic Acid
      • Sialyl SSEA-1/SLX
      • SN10
      • Somatostatin
      • TA-90
      • TABA
      • Tachykinin
      • TAG 12
      • TPS
      • Troponin
      • Tubulin
      • VCAM
      • VEGF
      • Villen
  • C. Instrumentation Review And Market Needs
    • 1. Abbott AxSYM
    • 2. Abbott Architect c4000
    • 3. Abbott Architect i2000 Series
    • 4. Abbott Architect ci8200 System
    • 5. Beckman Coulter UniCel Series
    • 6. Beckman Coulter Access
    • 7. Binding Site ESP600
    • 8. bioMerieux Mini Vidas
    • 9. Carolina Chemistries BioLis 24i
    • 10. DiaSorin Liaison
    • 11. Horiba ABX Pentra 400
    • 12. Inverness DS2
    • 13. J&J Vitros ECi/ECiQ
    • 14. J&J Vitros 3600
    • 15. J&J Vitros 5600
    • 16. Olympus AU5400
    • 17. Olympus AU3000i
    • 18. Olympus AU2700
    • 19. Roche Modular Analytics
    • 20. Roche Cobas Integra 400
    • 21. Roche Cobas Integra 400 Plus
    • 22. Roche Elecsys
    • 23. Roche Cobas c311
    • 24. Siemens ADVIA Centaur
    • 25. Siemens Dimension
    • 26. Siemens Dimension RxL Max
    • 27. Siemens Dimension Vista 500
    • 28. Siemens Immulite
    • 29. Siemens Stratus
    • 30. Tosoh AIA-Series
    • 31. Vital Diagnostics ATAC 8000
    • 32. Vital Diagnostics Envoy 500
  • D. Current and Emerging Technologies
    • 1. Monoclonal and Polyclonal Antibodies
    • 2. Immunoassays
      • a. Technological Principle
      • b. Radioimmunoassay (RIA)
      • c. Enzyme Immunoassays (EIA)
        • Overview
        • ELISA
        • Immunofiltration
        • Particle-Membrane Capture Immunoassay
        • Enzyme Amplification
      • d. Fluorescent Immunoassays
      • e. Luminescence
        • Chemiluminescence
        • Bioluminescence
      • f. Latex Agglutination
      • g. Immunoprecipitation
        • H. Affinity Chromatographu
        • e. Liposome Flow-Injection Immunoassay
    • 3. Molecular Diagnostics
      • a. Technology Overview
      • b. Amplification Methods
        • PCR
        • DAP-PCR
        • Immuno-PCR
        • QC-PCR
        • CAR
        • DNA
        • HPA
        • LCR
        • NASBA
        • QBR
        • SDA
        • 3 SR, and others
    • 4. Chromosome Analysis
      • a. Chronic Myelogenous Leukemia (CML)
      • b. Acute Myeloid Leukemia (AML)
      • c. Acute Lymphoblastic Leukemia (ALL)
      • d. Malignant Lymphomas
        • Lymphoid Malignancies
      • e. Chronic Lymphocytic Leukemia (CLL)
      • f. Solid Cancers
      • g. Chromosomal Translocation and Oncogenes
    • 5. Artificial Intelligence
    • 6. Flow Cytometry
    • 7. Two Dimensional Gel Electrophoresis (2-DGE)
    • 8. Biosensors
    • 9. Competing/Complementing Technologies
      • a. CT
      • b. MRI
      • c. NMR
      • d. PET
      • e. Photonics Spectroscopy
        • E. Personal Testing

U.S.A.

  • A. Executive Summary
  • B. Business Environment
    • 1. Health Care Expenditures
    • 2. Cost Consciousness
    • 3. Industry Consolidation
    • 4. Managed Care
    • 5. Hospitals
    • 6. Admissions
    • 7. Length of Stay
    • 8. Industry Diversification
    • 9. Physician Demographics
    • 10. Population Aging
      • a. Chronic Illness
      • b. Disease Incidence
      • c. Susceptibility to Iatrogenesis
      • d. Multiple Illness Cases
    • 11. Laboratory Regulations
  • C. Market Structure
    • 1. Centralized Testing
      • a. Hospitals
      • b. Commercial/Private Laboratories
    • 2. POT/Decentralized Testing
      • a. Physician Offices/Group Practices
      • b. Cancer Clinics
      • c. Point-Of-Care Testing
      • d. Other Decentralized Testing Locations
  • D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

Major Product Development Opportunities

  • A. Reagent Kits and Test Systems/Panels
  • B. Instrumentation
  • C. Computers, Software and Automation
  • D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies
    • 1. Marketing Approaches
    • 2. Product Complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

Competitive Profiles

  • Abbott
  • AdnaGen
  • Applied Gene Technologies
  • Arca
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Correlogic Systems
  • Dako
  • Decode
  • Diadexus
  • Diagnocure
  • Diasorin
  • Eiken Chemical
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Gen-Probe
  • Guided Therapeutics
  • Hologic
  • Ipsogen
  • Kreatech
  • Kyowa Medex
  • Life Technologies
  • Mackay Life Sciences
  • Myriad Genetics
  • Nanogen Elitech
  • OncoLab
  • Otho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zila

List of Tables

  • Tumor Marker Classification
  • Major Companies Developing or Marketing ACTH Tests
  • Major Companies Developing or Marketing AFP Tests
  • Major Companies Developing or Marketing Beta-2 Microglobulin Tests
  • Major Companies Developing or Marketing CA 15-3/27.29 Tests
  • Major Companies Developing or Marketing CA 19-9 Tests
  • Major Companies Developing or Marketing CA 125 Tests
  • Major Companies Developing or Marketing Calcitonin Tests
  • Major Companies Developing or Marketing CEA Tests
  • Major Companies Developing or Marketing Estrogen Receptor Tests
  • Major Companies Developing or Marketing Progesterone Receptor Tests
  • Major Companies Developing or Marketing Ferritin Tests
  • Major Companies Developing or Marketing Gastrin Tests
  • Major Companies Developing or Marketing HCG Tests
  • Major Companies Developing or Marketing Insulin Tests
  • Major Companies Developing or Marketing NSE Tests
  • Major Companies Developing or Marketing Occult Blood Tests
  • Major Companies Developing or Marketing PAP Smear/HPV Tests
  • Major Companies Developing or Marketing PAP Tests
  • Major Companies Developing or Marketing PSA Tests
  • Major Companies Developing or Marketing Lymphocyte Subclassification Tests
  • Biochemical Markers Potential Applications In Cancer Diagnosis
  • Oncogenes Potential Applications In Cancer Diagnosis
  • Major Companies Developing or Marketing Oncogene Tests
  • Growth Factors Potential Applications In Cancer Diagnosis
  • Colony Stimulating Factors Potential Applications in Cancer Diagnosis
  • Lymphokines Potential Applications In Cancer Diagnosis
  • Immunohistochemical Stains Potential Applications in Cancer Diagnosis
  • Executive Summary Table: U.S., Hospital Cancer Diagnostic Test Volume and Sales Forecast
  • U.S., Estimated New Cancer Cases and Deaths
  • U.S., Estimated Cancer Death Rates Per 100,000 Population
  • U.S., Laboratories Performing Cancer Diagnostic Tests
  • U.S., Hospital Laboratories Performing Cancer Diagnostics Tests by Bed Size
  • U.S., Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test
  • U.S., Total Cancer Diagnostics Sales By Major Supplier
  • U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
  • U.S., AFP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
  • U.S., CEA Testing Market Diagnostics Sales by Major Supplier
  • U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
  • U.S., HCG Testing Market Diagnostics Sales by Major Supplier
  • U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
  • U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
  • U.S., PAP Testing Market Diagnostics Sales by Major Supplier
  • U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
  • U.S., PSA Testing Market Diagnostics Sales by Major Supplier
Back to Top